Related references
Note: Only part of the references are listed.Optimized preparation and preliminary evaluation of [64Cu]-DOTA-trastuzumab for targeting ErbB2/Neu expression
Behrooz Alirezapour et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2013)
Production and quality control of [166Ho]-DOTA-bevacizumab for therapeutic applications
Alireza Khorami-Moghadam et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2012)
Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy
Hassan Yousefnia et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2011)
Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Hong Song et al.
CURRENT DRUG DELIVERY (2011)
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma
Gang Niu et al.
CLINICAL CANCER RESEARCH (2010)
Therapeutic Efficacy of Lu-177-CHX-A ''-DTPA-hu3S193 Radioimmunotherapy in Prostate Cancer Is Enhanced by EGFR Inhibition or Docetaxel Chemotherapy
Marcus P. Kelly et al.
PROSTATE (2009)
Cetuximab: Preclinical Evaluation of a Monoclonal Antibody Targeting EGFR for Radioimmunodiagnostic and Radioimmunotherapeutic Applications
Diane E. Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2008)
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines
Martin Eiblmaier et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Bernard M. Tijink et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Radiotherapy of human xenograft NSCLC tumors in nude mice with a 90Y-labeled anti-tissue factor antibody
BY Wang et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Epidermal growth factor receptor inhibition strategies in oncology
PM Harari
ENDOCRINE-RELATED CANCER (2004)
Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N,N′-tetraacetic acid for radiolabeling proteins
LL Chappell et al.
NUCLEAR MEDICINE AND BIOLOGY (2003)
Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2:: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells
CJ Smith et al.
NUCLEAR MEDICINE AND BIOLOGY (2003)
Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy
U Pandey et al.
APPLIED RADIATION AND ISOTOPES (2002)
Share Paper
